Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01143259 · ClinicalTrials.gov registry record · NA
Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use
A NA study, sponsored by Intermountain Health Care.
- Completed
- Registry status
- NA
- Development phase
- 274
- Enrollment target
NCT01143259: Completed NA study, sponsored by Intermountain Health Care.
NCT01143259 is a NA study that has completed, run by Intermountain Health Care. The registered enrollment target is 274 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01143259, a NA study, has completed, sponsored by Intermountain Health Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 274 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the addition of alvimopan to our care process model for colon resection patients will decrease length of stay. The care process model is a combination of optimal IV fluid management, early feeding, early ambulation, patient education, and pain management.
Primary Outcome
Determine if alvimopan addition to the multidisciplinary care process will result in decreased length of stay compared with the multidisciplinary care process plus placebo. Length of stay is determined by how many days a patient stays in the hospital. This is calculated by subtracting the discharge date from the admit date.
Interventions
- DRUG Alvimopam
- DRUG 300 mg Polyethylene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-08 |
| Phase | NA |
What the finished NCT01143259 record still lists
NCT01143259 is an interventional study that assigns participants to a tested intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Alvimopam is the first listed.
NCT01143259 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01143259 about?
NCT01143259 is a clinical study titled "Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use". The purpose of this study is to determine if the addition of alvimopan to our care process model for colon resection patients will decrease length of stay. The care process model is a combination of optimal IV fluid management, early feeding, early ambulation, patient education, and pain management.
What is the current status of trial NCT01143259?
This trial is currently completed. It is a NA study. The enrollment target is 274 participants. The study started on 2010-05. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01143259?
The interventions under investigation include: Alvimopam (DRUG), 300 mg Polyethylene (DRUG).
Who is sponsoring clinical trial NCT01143259?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01143259's enrollment target sits among peer trials
274 385th of 2000 higher than 1,615 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
- NCT05952583 · 274 participants
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia